SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guided Therapeutics - GTHP
GTHP 0.2700.0%Oct 31 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: RAVEL who wrote (28)8/27/1998 12:25:00 PM
From: BitWizrd  Read Replies (1) of 118
 
Integ gives up on IR altogether. Cannot bode well for SPRX. From quarterly earnings announcement:

"During the second quarter, we completed our large scale internal study that tested our LifeGuide System on more than 450 people with diabetes," said Susan L. Critzer, Integ vice president, operations and interim president. "The study has allowed us to draw definitive conclusions regarding the LifeGuide System performance and the steps required to bring our painless and bloodless technology to the market as quickly as possible".

According to Critzer, the study results:

-- Confirmed on a large patient population that the glucose concentration present in ISF is clinically equivalent to the glucose concentration in venous blood.

-- Demonstrated that Integ's proprietary sampling technology can reliably collect and deliver a one microliter sample of ISF fluid, a quantity sufficient for accurate measurement by multiple currently available technologies.

-- Showed that the Company's infrared technology for measuring glucose levels in ISF requires additional improvements to achieve clinically acceptable performance.

"Based on the study results, we have concluded that the shortest path to a small, lightweight commercial LifeGuide System is to incorporate a proven measurement technology, such as strips or biosensors. We are currently exploring various options, including evaluating potential corporate alliances that could expedite this integration. As part of our ongoing R&D efforts, we have demonstrated the near-term feasibility of integrating either electrochemical or colorimetric measurement technology with Integ's patented ISF sample collection technique.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News